Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease
MTEC-22-03- Diarrheal

Solicitation Number:  W81XWH-15-9-0001
MTEC Solicitations:  https://www.mtec-sc.org/solicitations/
PDF:    https://www.mtec-sc.org/wp-content/uploads/2021/12/MTEC-22-03-Diarrheal-RPP.pdf
See Upcoming Solicitations https://www.mtec-sc.org/solicitations/#Upcoming-Solicitations  
Enhanced White Papers are due no later than February 7, 2022 at 12:00pm Eastern Time.

The University of Iowa is a member of the MTEC Medical Technology Enterprise Consortium  https://www.mtec-sc.org

This RPP is focused on the development of a self-administered oral immunotherapy (not a vaccine) to prevent endemic diarrheal disease by targeting multiple bacterial pathogens. The self-
administered oral immunotherapy should mitigate symptoms, shorten the duration of illness, and/or reduce the risk of contracting bacterial diarrheal illnesses. The proposed immunotherapy product would target enterotoxigenic Escherichia coli (ETEC), and at least one other common bacterial diarrheal pathogen such as Campylobacter or Shigella. The oral immunotherapy must be stable without requiring a cold-chain and therefore could be utilized by the Warfighter in austere environments.